CO2023002206A2 - Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2 - Google Patents
Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2Info
- Publication number
- CO2023002206A2 CO2023002206A2 CONC2023/0002206A CO2023002206A CO2023002206A2 CO 2023002206 A2 CO2023002206 A2 CO 2023002206A2 CO 2023002206 A CO2023002206 A CO 2023002206A CO 2023002206 A2 CO2023002206 A2 CO 2023002206A2
- Authority
- CO
- Colombia
- Prior art keywords
- trem2
- agonist
- agonists
- colony
- treatment
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 title abstract 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000004064 dysfunction Effects 0.000 title abstract 2
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 abstract 4
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 abstract 4
- 229940105904 TREM-2 agonist Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 108091006084 receptor activators Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona un método para tratar una enfermedad o trastorno causado por y/o asociado con una disfunción del CSF1R en un paciente humano, el método comprende administrar al paciente que lo necesita una cantidad eficaz de un compuesto que aumenta la actividad del receptor activador expresado en células mieloides 2 (TREM2). En algunas modalidades, el compuesto que aumenta la actividad de TREM2 es un agonista de TREM2. En algunas modalidades, el agonista de TREM2 es un agonista de molécula pequeña de TREM2 o un agonista de anticuerpo de TREM2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061315P | 2020-08-05 | 2020-08-05 | |
| US202063129852P | 2020-12-23 | 2020-12-23 | |
| PCT/US2021/071115 WO2022032293A2 (en) | 2020-08-05 | 2021-08-05 | Treatment of diseases related to colony-stimulating factor 1 receptor dysfunction using trem2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023002206A2 true CO2023002206A2 (es) | 2023-06-09 |
Family
ID=80117708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0002206A CO2023002206A2 (es) | 2020-08-05 | 2023-02-27 | Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220089726A1 (es) |
| EP (1) | EP4192881A4 (es) |
| JP (1) | JP2023536916A (es) |
| KR (1) | KR20230061386A (es) |
| AU (1) | AU2021320553A1 (es) |
| BR (1) | BR112023002093A2 (es) |
| CA (1) | CA3190581A1 (es) |
| CO (1) | CO2023002206A2 (es) |
| CR (1) | CR20230069A (es) |
| IL (1) | IL300327A (es) |
| MX (1) | MX2023001546A (es) |
| TW (1) | TW202218683A (es) |
| WO (1) | WO2022032293A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020397888A1 (en) | 2019-12-05 | 2022-06-09 | Alector Llc | Methods of use of anti-TREM2 antibodies |
| WO2023192288A1 (en) * | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024052343A1 (en) * | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Trem-2 agonists for the treatment of marfan syndrome |
| WO2024097798A1 (en) * | 2022-11-01 | 2024-05-10 | Vigil Neuroscience, Inc. | Anti-trem2 antibody and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170240631A1 (en) * | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| AU2016334051B2 (en) * | 2015-10-06 | 2023-10-26 | Alector Llc | Anti-TREM2 antibodies and methods of use thereof |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| UY38407A (es) * | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| EP3887401A2 (en) * | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
-
2021
- 2021-08-05 JP JP2023507597A patent/JP2023536916A/ja active Pending
- 2021-08-05 CR CR20230069A patent/CR20230069A/es unknown
- 2021-08-05 EP EP21854032.6A patent/EP4192881A4/en active Pending
- 2021-08-05 AU AU2021320553A patent/AU2021320553A1/en active Pending
- 2021-08-05 BR BR112023002093A patent/BR112023002093A2/pt not_active Application Discontinuation
- 2021-08-05 MX MX2023001546A patent/MX2023001546A/es unknown
- 2021-08-05 IL IL300327A patent/IL300327A/en unknown
- 2021-08-05 TW TW110128963A patent/TW202218683A/zh unknown
- 2021-08-05 US US17/444,511 patent/US20220089726A1/en not_active Abandoned
- 2021-08-05 KR KR1020237007468A patent/KR20230061386A/ko unknown
- 2021-08-05 CA CA3190581A patent/CA3190581A1/en active Pending
- 2021-08-05 WO PCT/US2021/071115 patent/WO2022032293A2/en active Application Filing
-
2023
- 2023-02-27 CO CONC2023/0002206A patent/CO2023002206A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220089726A1 (en) | 2022-03-24 |
| KR20230061386A (ko) | 2023-05-08 |
| TW202218683A (zh) | 2022-05-16 |
| EP4192881A2 (en) | 2023-06-14 |
| WO2022032293A2 (en) | 2022-02-10 |
| CA3190581A1 (en) | 2022-02-10 |
| AU2021320553A1 (en) | 2023-03-02 |
| WO2022032293A3 (en) | 2022-03-31 |
| BR112023002093A2 (pt) | 2023-04-25 |
| CR20230069A (es) | 2023-08-16 |
| IL300327A (en) | 2023-04-01 |
| JP2023536916A (ja) | 2023-08-30 |
| EP4192881A4 (en) | 2024-08-14 |
| MX2023001546A (es) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023002206A2 (es) | Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2 | |
| RU2010108429A (ru) | Регуляторы ммр-9 и их применение | |
| CO5670356A2 (es) | Programa de dosificaicon para un nuevo agente anticanceroso | |
| Przeklasa-Muszyńska et al. | Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients | |
| CL2022002813A1 (es) | Semaglutida para el tratamiento de esteatohepatitis no alcoholica. | |
| Shan et al. | Naringenin attenuates fibroblast activation and inflammatory response in a mechanical stretch-induced hypertrophic scar mouse model | |
| UY39328A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting | |
| BR112023022264A2 (pt) | Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo | |
| BR112022021823A2 (pt) | Métodos para tratar doenças associadas à mielina e doenças associadas à mitocôndria | |
| CL2023000856A1 (es) | Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer | |
| CL2021002966A1 (es) | Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer. | |
| UY39608A (es) | Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting | |
| MX2023006397A (es) | Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2. | |
| CO2023013442A2 (es) | Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos | |
| UY31786A1 (es) | Inhibidores de la expresion y la actividad del pai-1 para el tratamiento de trastornos oculares | |
| CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
| AR118191A1 (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa | |
| Fahy et al. | The adrenergic system in plastic and reconstructive surgery: physiology and clinical considerations | |
| Najafpour et al. | Vitamin C pre-medication enhances the anaesthetic effect of ketamine-xylazine combination in the rat | |
| Hossain et al. | Dexamethasone for prevention of postoperative shivering: a prospective clinical study | |
| Abdulrahman et al. | A study of α-Adrenoceptor agonists on porcine nasal and extra-nasal vasculature: insight into decongestant activity | |
| ECSP23076276A (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| AR123760A1 (es) | Métodos para tratar el cáncer | |
| AR123576A1 (es) | Métodos para tratar el cáncer | |
| Martelletti et al. | 115 Economic burden among migraine patients: United Kingdom perspective |